- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT05159245
O estudo nacional finlandês para facilitar o acesso do paciente a medicamentos anticancerígenos direcionados (FINPROVE)
O estudo nacional finlandês para facilitar o acesso do paciente a medicamentos anticancerígenos direcionados para determinar a eficácia no tratamento de cânceres avançados com um perfil molecular conhecido
This is a prospective non-randomized national clinical phase 2 trial that aims to determine the efficacy and toxicity of targeted anticancer drugs or combinations that are approved or under review by EMA, FDA or PMDA and are used for treatment of patients with advanced cancer with a potentially actionable variant as revealed by a genomic, RNA-molecular or protein expression test.
Visão geral do estudo
Status
Intervenção / Tratamento
- Medicamento: Alectinib
- Medicamento: Cobimetinib
- Medicamento: Vismodegib
- Medicamento: Trastuzumab+Pertuzumab
- Medicamento: Entrectinib
- Medicamento: Atezolizumab
- Medicamento: Vemurafenib
- Medicamento: Regorafenib
- Medicamento: Apalutamide
- Medicamento: Abemaciclib
- Medicamento: Tepotinib
- Medicamento: Dabrafenib
- Medicamento: Trametinib
- Medicamento: Dabrafenib+Trametinib
- Medicamento: Pemigatinib
Descrição detalhada
This is a prospective non-randomized clinical trial that aims to determine the efficacy and toxicity of targeted anticancer drugs or combinations that are approved or under review by EMA, FDA or PMDA and are used for treatment of patients with advanced cancer with a potentially actionable variant as revealed by a genomic, RNA-molecular or protein expression test. The study also aims to facilitate patient access to approved targeted therapies that are contributed to the program by collaborating pharmaceutical companies and to perform next generation sequencing and further deeper analysis on tumor biopsies and/or liquid biopsies for biomarker analyses and resistance mechanisms. Eligible patients have an advanced cancer for which standard treatment options no longer exist and acceptable performance status and organ function. A tumour DNA, RNA or protein expression analysis is required and the results must identify at least one potentially actionable molecular variant as defined in the protocol. Molecular profiling will be utilized to determine an appropriate drug(s) from among those available in the protocol. Drug selection will be guided by a list of potential profiles, the molecular tumor board and databases of identified targets for review and approval of the recommended treatment. The protocol-specified treatment will be administered to the patient once any drug- and disease specific eligibility criteria and overall study criteria are met. Data for standard efficacy outcomes including tumor response, progression-free and overall survival as well as duration of treatment will be collected for all patients receiving treatment within the trial. In addition, treatment related toxicity will be collected according to CTCAE 5.0.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
Contactos e Locais
Contato de estudo
- Nome: Tanja Juslin
- Número de telefone: +358405597415
- E-mail: tanja.juslin@hus.fi
Locais de estudo
-
-
-
Kuopio, Finlândia
- Recrutamento
- Kuopio University Hospital
-
Contato:
- Okko Kääriäinen, MD
-
Oulu, Finlândia
- Recrutamento
- Oulu University Hospital OYS Cancer Center
-
Contato:
- Sanna Iivanainen, MD. PhD.
-
Tampere, Finlândia
- Recrutamento
- Tampere University Hospital Department of Oncology
-
Contato:
- Minna Tanner, MD, PhD
-
-
Southwest Finland
-
Turku, Southwest Finland, Finlândia
- Recrutamento
- Turku University Hospital Cancer Centre
-
Contato:
- Erika Alanne, MD, PhD
-
-
Uusimaa
-
Helsinki, Uusimaa, Finlândia, 00029
- Recrutamento
- Helsinki University Hospital Comprehensive Cancer Center
-
Contato:
- Tanja Juslin
-
Investigador principal:
- Katriina Jalkanen, MD, PhD
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Adult (age >18 years) patient with a histologically-confirmed locally advanced or metastatic cancer who is no longer benefitting from standard anti-cancer treatment or for whom no such treatment is available or indicated.
-
ECOG performance status 0-2
-
Patients must have acceptable organ function as defined below. However, specific inclusion/exclusion criteria specified in the drug-specific study manual will take precedence:
- Absolute neutrophil count ≥ 1.5 x 109/l
- Hemoglobin > 8.0 mmol/l, without blood transfusion within 7 days
- Platelets > 75 x 109/l (not applicable for hematological patients)
- Total bilirubin < 1.5 x ULN
- AST and ALT < 3 x institutional ULN (or < 5 x ULN in patients with known hepatic metastases)
- Serum creatinine ≤ 1.5 × ULN or calculated or measured creatinine clearance ≥ 40 mL/min/1.73 m2
-
Patients must have objectively evaluable or measurable disease (by physical or radiographic examination, according to RECIST v1.1, Lugano, IWG and ELN-AML, IMWG, RANO, GCIG, iRESIST or PCWG3.
-
Results must be available from a tumor molecular profiling. Eligible tests may include any of the following technologies: fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), comparative genomic hybridization (CGH), next generation sequencing (NGS) or immunohistochemistry (IHC). The test may have been performed on the primary tumor or a metastatic lesion, in a diagnostic laboratory or within the context of another commercial platform (eg Foundation Medicine), and must reveal a potentially actionable variant.
-
Patients must have a tumor profile for which treatment with one of the approved (or under revision for approval) targeted anti-cancer drugs included in this study has potential clinical benefit based on preclinical data or clinical information.
-
A new (obtained ≤6 months before inclusion after which no further anti-cancer therapy is allowed) fresh frozen and FFPE tumor biopsy specimen or liquid biopsy for extensive biomarker testing is mandatory before the start of treatment with a targeted agent included in the protocol.
-
Ability to understand and the willingness to sign a written informed consent document and comply to the protocol.
-
For orally administered drugs, the patient must be able to swallow and tolerate oral medication and must have no known malabsorption syndrome.
-
Because of the risks of drug treatment to the developing fetus, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation, and for four months following completion of study therapy. Male patients should avoid impregnating a female partner. Male patients, even if surgically sterilized, (i.e. post-vasectomy) must agree to one of the following: practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug, or completely abstain from sexual intercourse.
Exclusion Criteria:
-
Ongoing toxicity > grade 2, other than alopecia or > grade 1 neuropathy.
-
Patient is receiving any other anti-cancer therapy (cytotoxic, biologic, radiation, or hormonal other than for replacement). Required wash out period prior to starting study treatment is at least two weeks. An exception is made for:
- Patients suffering from CRPC are allowed to continue androgen deprivation therapy.
- Medications that are prescribed for supportive care but may potentially have an anti-cancer effect (e.g., megestrol acetate, bisphosphonates). These medications must have been started ≥ 1 week prior to enrollment on this study.
-
Received colony-stimulating factors (eg, G-CSF, GM-CSF or recombinant EPO) within 14 days prior to the first dose of study intervention
-
Patient is pregnant or nursing.
-
Patients with known active progressive brain metastases. Patients with previously treated brain metastases are eligible, provided that the patient is clinically stable and off steroids for at least 4 weeks prior to study initiation. GMB patients apply additional exclusion criteria.
-
Patients with clinically significant preexisting cardiac conditions, including uncontrolled or symptomatic angina, uncontrolled atrial or ventricular arrhythmias, or symptomatic congestive heart failure are not eligible.
-
Patients with clinically significant preexisting cardiac conditions, including uncontrolled or symptomatic angina, uncontrolled atrial or ventricular arrhythmias, or symptomatic congestive heart failure are not eligible.
-
Patients with known left ventricular ejection fraction (LVEF) < 45% are not eligible
-
Patients with stroke (including TIA) or acute myocardial infarction within 3 months before the first dose of study treatment are not eligible
-
Patients with any other clinically significant medical condition which, in the opinion of the treating physician, makes it undesirable for the patient to participate in the study or which could jeopardize compliance with study requirements including, but not limited to: ongoing or active infection, significant uncontrolled hypertension, or severe psychiatric illness/social situations.
For each drug included in this protocol, specific inclusion and exclusion criteria (based on the Package Insert or manufacturers recommendations) may also apply. Drug-specific inclusion and exclusion criteria will take precedence over the inclusion/exclusion criteria listed above.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Alectinib
For patients with a molecular tumor profile that can potentially be targeted by alectinib. |
ALK
Outros nomes:
|
|
Experimental: Cobimetinib
For patients with a molecular tumor profile that can potentially be targeted by cobimetinib. |
MEK1, MEK2
Outros nomes:
|
|
Experimental: Vismodegib
For patients with a molecular tumor profile that can potentially be targeted by vismodegib. |
Hedgehog
Outros nomes:
|
|
Experimental: Trastuzumab+Pertuzumab
For patients with a molecular tumor profile that can potentially be targeted by trastuzumab+pertuzuma combination. |
HER2
Outros nomes:
|
|
Experimental: Entrectinib
For patients with a molecular tumor profile that can potentially be targeted by entrectinib. |
NTRK/ ROS1, ALK
Outros nomes:
|
|
Experimental: Atezolizumab
For patients with a molecular tumor profile that can potentially be targeted by atezolizumab. |
PD-L1
Outros nomes:
|
|
Experimental: Vemurafenib
For patients with a molecular tumor profile that can potentially be targeted by vemurafenib. |
BRAF V600
Outros nomes:
|
|
Experimental: Regorafenib
For patients with a molecular tumor profile that can potentially be targeted by regorafenib. |
KIT/BRAF, RET
Outros nomes:
|
|
Experimental: Apalutamide
For patients with a molecular tumor profile that can potentially be targeted by apalutamide. |
AR
Outros nomes:
|
|
Experimental: Abemaciclib
For patients with a molecular tumor profile that can potentially be targeted by abemaciclib. |
CDK4/6
Outros nomes:
|
|
Experimental: Tepotinib
For patients with a molecular tumor profile that can potentially be targeted by tepotinib. |
MET ex14
Outros nomes:
|
|
Experimental: Dabrafenib
For patients with a molecular tumor profile that can potentially be targeted by dabrafenib. |
RAF
Outros nomes:
|
|
Experimental: Trametinib
For patients with a molecular tumor profile that can potentially be targeted by trametinib. |
MEK1, MEK2
Outros nomes:
|
|
Experimental: Dabrafenib+Trametinib
For patients with a molecular tumor profile that can potentially be targeted by dabrafenib+trametinib combination. |
RAF, MEK1, MEK2
Outros nomes:
|
|
Experimental: Pemigatinib
For patients with a molecular tumor profile that can potentially be targeted by pemigatinib. |
FGFR2
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Disease control rate
Prazo: 16 weeks
|
Disease control rate at 16 weeks after treatment initiation (defined as patients by CR, PR, SD) |
16 weeks
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Duration of treatment
Prazo: 5 years
|
Time on drug |
5 years
|
|
Adverse Events
Prazo: 5 years
|
Treatment-related grade ≥3 and serious adverse events |
5 years
|
|
Overall response
Prazo: 5 years
|
Best overall response (defined as patients by CR, PR, SD) |
5 years
|
|
PFS
Prazo: 5 years
|
Progression free survival |
5 years
|
|
OS
Prazo: 5 years
|
Overall survival |
5 years
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Katriina Jalkanen, MD, PhD, Helsinki University Hospital Comprehensive Cancer Centre
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Neoplasias por local
- Neoplasias
- Doenças Hematológicas
- Doenças hemic e linfáticas
- Neoplasias Hematológicas
- Compostos de enxofre
- Produtos químicos orgânicos
- Compostos heterocíclicos
- Compostos heterocíclicos, 2 anel
- Compostos heterocíclicos, anel fundido
- Amidas
- Indoles
- Sulfonamidas
- Sulfonas
- Vemurafenibe
- abemaciclib
- Dabrafenib
- Trametinibe
- Atezolizumab
- Cobimetinibe
- Regorafenib
- Entrectinib
- Pemigatinib
- Alectinib
- Apalutamida
- Hhantag691
- tepotinib
Outros números de identificação do estudo
- FINPROVE
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Investigators plan to share the clinical study report.
Prazo de Compartilhamento de IPD
2026-2027
Critérios de acesso de compartilhamento IPD
Will be made available through European regulatory CTIS programme.
Tipo de informação de suporte de compartilhamento de IPD
- CSR
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .